Nyxoah Sa (NYXH)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nyxoah Sa Stock (NYXH) Company Profile

Healthcare (1064)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NYXH's Discussions on Twitter

Compare NYXH vs ISRG, BDX, RMD, MDLN, ALC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NYXH Nyxoah Sa	1.36	147.67M	17.85M	-96.93M	-88.29M	-2.4735
ISRG Intuitive Surgical Inc	391.95	143.14B	11.03B	3.16B	3.22B	8.7251
BDX Becton Dickinson Co	176.80	50.07B	21.37B	1.41B	3.07B	3.9437
RMD Resmed Inc	218.89	32.02B	5.54B	1.52B	1.74B	10.37
MDLN Medline Inc	35.61	30.44B	29.14B	1.07B	1.05B	1.1956
ALC Alcon Inc	63.76	31.16B	10.63B	819.00M	1.59B	1.6577

Nyxoah Sa Stock (NYXH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-07-31	Eingeleitet	H.C. Wainwright	Buy
2023-07-19	Eingeleitet	Robert W. Baird	Neutral
2022-04-21	Eingeleitet	Oppenheimer	Outperform
2022-04-06	Eingeleitet	Wolfe Research	Peer Perform
2021-12-21	Fortgesetzt	Cantor Fitzgerald	Overweight
2021-07-28	Eingeleitet	Cantor Fitzgerald	Overweight

Alle ansehen

Nyxoah Sa Aktie (NYXH) Neueste Nachrichten

Finanzdaten der Nyxoah Sa-Aktie (NYXH)

Nyxoah Sa (NYXH)

Nyxoah Sa Stock (NYXH) Company Profile

Compare NYXH vs ISRG, BDX, RMD, MDLN, ALC

Nyxoah Sa Stock (NYXH) Upgrades & Downgrades

Nyxoah Sa Aktie (NYXH) Neueste Nachrichten

Nyxoah (NASDAQ: NYXH) Stock Price, News & Analysis - Kalkine

With Genio approved by the FDA and launched in the U.S., Nyxoah (NYXH) names a new CEO - Stock Titan

Nyxoah Appoints New CEO to Drive US Expansion - Sleep Review

Discontinued operations of Nyxoah SA – HAN:5YI - TradingView

Nyxoah names Liam Kelly as CEO - Medical Buyer

Nyxoah SA Announces CEO Changes, Effective October 1, 2026 - marketscreener.com

A former medical-device CEO will lead Nyxoah while its U.S. launch is still in early stages. - Stock Titan

Nyxoah Appoints Liam Kelly as Chief Executive Officer - GlobeNewswire

Nyxoah Names Former CFO Loïc Moreau as Interim Finance Chief, Reaffirms 2026 Guidance - The Globe and Mail

CFO John Landry to leave Nyxoah (NASDAQ: NYXH) in 2026 as company searches for his successor - Stock Titan

NYXH.BB Price History for Nyxoah Sa Stock - Barchart.com

Nyxoah shares fall after CFO departure announcement - Investing.com

Nyxoah shares fall after CFO departure announcement By Investing.com - Investing.com Australia

Nyxoah announces CFO transition, reaffirms 2026 guidance By Investing.com - Investing.com India

Nyxoah announces CFO transition, reaffirms 2026 guidance - Investing.com

A medical technology company expects €36M–€40M in 2026 revenue. Nyxoah’s finance chief is set to leave. - Stock Titan

Nyxoah Announces Chief Financial Officer Transition - Finansavisen

Nyxoah SA(ENXTBR: NYXH) dropped from S&P Global BMI Index - marketscreener.com

Cantor Fitzgerald reiterates Nyxoah stock Overweight rating at $6 By Investing.com - Investing.com South Africa

Nyxoah (NYXH) Begins BREATHE Study. Can Real-World Evidence Drive Genio Adoption? - Yahoo Finance

Nyxoah SA Actuals & Estimates (HAM:5YI) - TradingView

Gross profit of Nyxoah SA – HAM:5YI - TradingView

Price to book ratio of Nyxoah SA – HAM:5YI - TradingView

Nyxoah Begins U.S. Post-Approval Study of Genio Sleep Apnea Implant - finance.biggo.com

Cash per share of Nyxoah SA – HAM:5YI - TradingView

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial - Yahoo Finance

Nyxoah implants first patient in BREATHE study of Genio - Yahoo

symbol__ Stock Quote Price and Forecast - CNN

Nyxoah Launches Major U.S. Post-Approval Study for Genio Sleep Apnea Device - TipRanks

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System - GlobeNewswire

The trading volume of these stocks is deviating from the norm in today's session. - ChartMill

Nyxoah SA (NYXH) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Cantor Fitzgerald reiterates Nyxoah stock rating on trial success By Investing.com - Investing.com Canada

Cantor Fitzgerald reiterates Nyxoah stock rating on trial success - Investing.com

Nyxoah stock rises on pivotal trial win for Genio (NYXH:NASDAQ) - Seeking Alpha

Nyxoah stock surges as sleep apnea study hits endpoints By Investing.com - Investing.com India

NYXH Jumps As ACCCESS Trial Data Reset The Trading Map - timothysykes.com

NYXH Stock Jumps As ACCCESS Trial De‑Risks Sleep Apnea Bet - StocksToTrade

NYXH Stock Pops As ACCCESS Trial Data Fuels Breakout Hopes - timothysykes.com

NYXH Stock Jumps As ACCCESS Trial De-Risks U.S. Growth Story - StocksToTrade

Nyxoah stock surges as sleep apnea study hits endpoints - Investing.com

87.7% improved on a measure of oxygen drops during sleep. No device-related serious adverse events were reported. - Stock Titan

Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary - GlobeNewswire

Nyxoah SA (NYXH) Stock Price & News - Syfe

Information on the total number of voting rights and shares - Finansavisen

Nyxoah (NYXH) Results Versus Estimates: The Available Earnings Metric Delivers a Miss in the Current Update; Market Reaction: The Share Price Sheds 2.74% in the Current UpdateEarnings Power Value - vinanet.vn

Nyxoah (NYXH) Latest: Falls 2.74% to $1.60 in Latest Trading; Price Context: the Current Price Sits Inside the Supplied Technical Range at the CloseIndex Put Call - vinanet.vn

Cantor Fitzgerald cuts Nyxoah stock price target on valuation By Investing.com - Investing.com Nigeria

Cantor Fitzgerald cuts Nyxoah stock price target on valuation - Investing.com

Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price - MarketBeat

NYXH Q2 2026 Earnings: EPS Miss of 46.48% Overshadowed by 2.53% Share GainCapex Guidance - vinanet.vn

Finanzdaten der Nyxoah Sa-Aktie (NYXH)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NYXH